Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,752 total articles
Investor sentiment has swung from euphoric to fearful around Nvidia. The company's secular exposure to AI remains intact; the panic creates a tactical long opportunity. This trade lays out entry, stop, targets, catalysts and the risks to consider over a 180 trading day horizon.
Uber has the scale, margins and cash generation to be a primary beneficiary of quick-commerce (q-commerce) expansion. The stock pulled back into the mid-$70s, offering a tactical long entry to capture upside from delivery mix improvement, autonomous vehicle partnerships, and holiday season demand. This is a swing trade: enter at $72.52, target $85.…
<p>Richtech Robotics (RR) is a small-cap robotics play trading at $1.65 with a market capitalization of roughly $371M, nearly $82M in cash, and an enterprise value of $69.6M. Recent board-approved buybacks and trade-show visibility give the stock several near-term catalysts while governance and profitability remain material negatives. This is an ac…
Constellation Energy (CEG) has seen its stock reprice lower in 2026 despite clear fundamental drivers: the Calpine acquisition added scale (22 GW), long-term PPAs with Microsoft and Meta are locking in cash flows, and management just raised guidance. At current levels the market is pricing in short-term timing and financing risk rather than long-te…
Shares of Corning (GLW) plunged after reports of a near-term equity distribution and renewed AI-slowdown chatter. The selloff creates a mid-term trade opportunity. Corning still carries high valuation multiples (PE ~75) but has durable free cash flow ($2.395B), a multi-year Verizon fiber deal, and exposure to AI-driven optical connectivity growth. …
Lionsgate's deep content library and improving cash generation create a favorable risk-reward for a position trade. I lay out an entry at $6.00, a stop at $4.50 and a target of $9.00 with a 180-trading-day horizon, anchored on licensing cadence, debt management and potential strategic deals.
GXO has underperformed this year despite clear signs of reacceleration in new business and a management plan to lift margins. The stock has dropped to the low $45s, offering a defined-risk long trade into an upcoming period of catalysts. I consider a mid-term swing trade here: enter near $45.87, stop at $43.00, and target $60.00 if momentum and mar…
Sandisk is trading at $1,543 after a dramatic recovery from last year’s low. Strong customer demand, rising NAND prices and the industry's move to multiyear Strategic Customer Agreements are creating a clearer revenue runway. This is a tactical long idea: enter near $1,540, stop at $1,450, target $1,850 over a mid-term 45 trading day horizon, with …
Freeport-McMoRan (FCX) is priced for modest cash generation today: free cash flow was $1.811B on a market cap near $99.4B. That math yields a low current FCF yield. But if Grasberg - one of the company's largest, highest-margin copper-gold assets - meaningfully recovers and copper prices hold, Freeport can generate several billion more in FCF. This…
Nissan is cheap by conventional balance-sheet measures and is executing structural upgrades that can unlock margins and free cash flow over the next 6-12 months. This trade idea takes a constructive, risk-aware long stance with a clearly defined entry, stop and target and a 180-trading-day horizon to allow organizational changes and alliance-driven…
Microsoft is trading at $504.54 after a sustained recovery from the $349 52-week low. Fundamentals - $67B in free cash flow, ROE north of 30%, low leverage - back a thesis that the company can extend its rally. This is a mid-term swing trade: entry $504.54, stop $462.00, target $545.00 (45 trading days) with clear risk-management and contingent tri…
Qualcomm's shift from smartphones toward data-center AI chips is real and measurable. A major AWS deal and growing AI momentum justify a long trade with disciplined risk controls. This plan outlines why, how, and what could go wrong.
Trekor Metals (TGB) has moved from promise to production with the first Florence copper cathode harvest. The market is still pricing the company like a single-asset explorer despite a $2.85B market cap, multiple development-stage projects and improving cash flow potential. This trade idea takes a constructive stance: buy a defined position on weakn…
APi Group (APG) sits at the intersection of recurring life-safety services and infrastructure maintenance. With free cash flow of $676M, recent M&A adding ~$90M of revenue, and activist/insider interest, APG is positioned to monetize the infrastructure cycle through both organic service growth and bolt-on acquisitions. Technical indicators show nea…
Galderma’s heavy launch investments are starting to show in market momentum and expanding opportunity sets across rosacea, hyperpigmentation and aesthetic injectables. At a $45.5B market cap and a PE near 51, the stock already prices growth; I expect product ramps and margin expansion to drive a re-rating over the next 180 trading days, while keepi…
Bristow Group (VTOL) is a lean, cash-generating helicopter and aviation services contractor trading at roughly $1.27B market cap and a 12x P/E. With management keeping 2026 adjusted EBITDA guidance intact and recent top-line strength, the stock offers asymmetric upside from operating leverage. This trade idea outlines an entry at $42.76 with a clea…
Delta’s ownership of a refinery is more than PR - it meaningfully lowers jet fuel cost exposure, stabilizes margins and creates a tactical buying opportunity after recent weakness. This trade targets a rebound as crude volatility and improved refinery economics flow through to airline margins.
Adobe beat on Q3, raised guidance, and reported accelerating AI monetization, yet the stock trades at a depressed multiple and near-cycle cash generation that argue the worst-case AI outcome is already priced. This trade targets a mid-term rebound while limiting downside with a tight stop.
Saturn Oil's share price has tripled, but the underlying project economics and small-cap valuation still leave room for a disciplined long trade. The set-up works if near-term production and cash generation keep improving and if commodity fundamentals remain supportive. Trade plan included with entry at $1.50, stop at $1.00 and primary/secondary ta…
NRX Pharmaceuticals is a clinical-stage biotech focused on NMDA-platform therapies. With a preservative-free ketamine ANDA advancing toward potential approval, recent commercial preparation and a $20M follow-on raise, and an active short base, NRXP offers a high-risk, high-reward swing trade. Entry at $3.42, target $5.00, stop $2.60 — mid-term hori…
Berkshire Hathaway offers a compelling long trade right now: deep cash reserves, steady free cash flow, aggressive buybacks and a diversified business mix create asymmetric upside with limited downside. We'll lay out an entry, stop and target with time-horizon logic and clear risks.
Devon Energy is trading near $51 with a tidy balance sheet, attractive EV/EBITDA of 7.6x, and recent liability management tied to the Coterra deal. With oil prices likely to stay supportive and integration risk receding after a successful note exchange, this is a mid‑term long idea targeting $60 with a clear stop at $46.50.
Lifecore is a small-cap CDMO with proven hyaluronan capabilities and fresh commercial site transfers that can reaccelerate revenue. The balance sheet and recent guidance cut are real concerns, but the stock's valuation, contract pipeline and elevated short interest create an asymmetric trade for disciplined, risk-aware buyers.
T1 Energy's G2_Austin project is scheduled to materially ramp production and lower unit costs starting in 2027. If the build stays on schedule and commissioning delivers modeled throughput, the company should see a step-change in free cash flow that the market has not fully priced. This is a directional long trade with a measured stop and a multi-m…
Inhibrx (INBX) is a clinical-stage biotech with two near-term, high-impact catalysts: a PDUFA action date for ozekibart (INBRX-109) in April 2027 and Phase 2 PFS data for INBRX-106 expected in Q4 2026. The balance sheet ($161.7M cash after a $75M debt raise), improving operating losses and a market cap near $1.56B create an asymmetric risk/reward f…
